TP53 and cancer: In this regard, it is important to emphasise that LFS represents a paradigm in genetic predisposition to cancer, considering the pivotal role of TP53 in the response to DNA and that its germline mutations are the fundamental to diagnose LFS, which has considerably evolved since its original definition in 1969 by Frederick Li and Joseph Fraumeni [85,87,88,89,90,91,92,93].